$-0.10 EPS Expected for OncoCyte Corporation (OCX)

July 14, 2018 - By Jenna Rose

OncoCyte Corporation (NYSEAMERICAN:OCX) Logo

Analysts expect OncoCyte Corporation (NYSEAMERICAN:OCX) to report $-0.10 EPS on August, 13.They anticipate $0.03 EPS change or 23.08 % from last quarter’s $-0.13 EPS. After having $-0.12 EPS previously, OncoCyte Corporation’s analysts see -16.67 % EPS growth. The stock decreased 3.08% or $0.1 during the last trading session, reaching $3.15. About 82,913 shares traded. OncoCyte Corporation (NYSEAMERICAN:OCX) has declined 58.26% since July 14, 2017 and is downtrending. It has underperformed by 70.83% the S&P500.

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine diagnostic tests for the early detection of cancer. The company has market cap of $124.13 million. The firm is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer. It currently has negative earnings. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.